FENNEC PHARMACEUTICALS INC. 8-K

What Happened

• Fennec Pharmaceuticals, Inc. (FENC) filed a Current Report on Form 8-K on May 22, 2026, disclosing that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as part of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting program. A press release dated May 21, 2026 announcing the presentations is furnished as Exhibit 99.1 to the 8-K.

Key Details

• 8-K filed: May 22, 2026; press release dated May 21, 2026 (Exhibit 99.1).
• Topic: New research on PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types.
• Disclosure type: Regulation FD disclosure furnished with the filing; the exhibit is furnished, not “filed” for purposes of Section 18 of the Securities Exchange Act.

Why It Matters

• The company is publicly disclosing additional clinical research on its marketed oncology product, PEDMARK, at a major scientific meeting (ASCO). For investors, presentation of new data at ASCO typically raises the profile of a drug’s clinical evidence and can increase visibility among clinicians, researchers, and potential partners. The 8-K ensures the market is informed of the company’s planned scientific disclosures; details of the actual data and timing will be in the ASCO program and the company’s press materials.